CERENIS Therapeutics

Cash Position and Activity Update for Q1 2019

Regulatory News:

CERENIS Therapeutics (FR0012616852 – CEREN – PEA-PME eligible), an international biopharmaceutical company dedicated to the discovery and development of innovative therapies for treating cardiovascular and metabolic diseases, as well as new HDL-based vectors for targeted drug delivery in the field of oncology and immuno-oncology, announces today that cash and cash equivalents totaled €9.7 million at March 31, 2019, the company having not generated any revenue during the 1^st quarter of 2019.

In addition, following expressions of interest, discussions are underway for its product CER-002, which is a specific agonist for PPARδ.

About CERENIS

Founded in 2005, Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative therapies. Cerenis’ expertise has translated into a rich portfolio of programs for the treatment of cardiovascular disease and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno-oncology and chemotherapy.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190418005535/en/